HCW Biologics Inc. (HCWB): Nasdaq/NYSE listing notice — HCW Biologics receives Nasdaq delisting notice for bid price and MVPHS noncompliance

HCW Biologics Inc.

Failed to regain compliance with minimum bid price ($1.00) by Feb 3, 2025 and MVPHS ($15M) by Feb 4, 2025.
Nasdaq Staff notified company on Feb 5, 2025 that securities are subject to delisting unless hearing requested.
Company plans to request hearing before Nasdaq Hearing Panel; will present plan to evidence compliance.
Previously disclosed noncompliance with MVLS Rule; hearing request stays delisting action pending panel decision.
No assurance that Panel will grant continued listing or that compliance can be achieved.

item 3.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

HCW Biologics Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5810(c)(3)(A)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5810(c)(3)(A)

Exact text from the filing

February 5, 2025, the Staff notified the Company that its securities were subject to delisting from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearing Panel (the “Panel”). As previously disclosed on December 23, 2024, the Company received written notice from the Staff regarding for the 30 consecutive business days ended June 17, 2024, the Company’s market value of listed securities (“MVLS”) closed below the $50,000,000 MVLS threshold required for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5450(b)(3)(A) (the “MVLS Rule”). The Company was g

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

HCW Biologics Inc. received a nasdaq delisting notice notice regarding other (rules 5810(c)(3)(A), 5450(b)(2)).

Exchange: nasdaq
Notice: delisting notice
Rules: 5810(c)(3)(A), 5450(b)(2)

Exact text from the filing

February 5, 2025, the Staff notified the Company that its securities were subject to delisting from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearing Panel (the “Panel”). As previously disclos

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

HCW Biologics Inc. received a nasdaq delisting notice notice regarding market value (rules 5450(b)(2)(C)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: market value
Rules: 5450(b)(2)(C)

Exact text from the filing

February 5, 2025, the Staff notified the Company that its securities were subject to delisting from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearing Panel (the “Panel”). As previously disclosed on December 23, 2024, the Company received written notice from the Staff regarding for the 30 consecutive business days ended June 17, 2024, the Company’s market value of listed securities (“MVLS”) closed below the $50,000,000 MVLS threshold required for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5450(b)(3)(A) (the “MVLS Rule”). The Company was g

View on SEC.gov

Browse all listing & compliance notices →

HCW Biologics Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-016390

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.